226 related articles for article (PubMed ID: 15492286)
1. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
2. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
3. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
4. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
7. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
8. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
Singh R; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
11. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
Abe F; Dafferner AJ; Donkor M; Westphal SN; Scholar EM; Solheim JC; Singh RK; Hoke TA; Talmadge JE
Cancer Immunol Immunother; 2010 Jan; 59(1):47-62. PubMed ID: 19449184
[TBL] [Abstract][Full Text] [Related]
16. Antimetastatic activity of a preventive cancer vaccine.
Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
[TBL] [Abstract][Full Text] [Related]
17. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice.
Wei WZ; Jacob JB; Zielinski JF; Flynn JC; Shim KD; Alsharabi G; Giraldo AA; Kong YC
Cancer Res; 2005 Sep; 65(18):8471-8. PubMed ID: 16166327
[TBL] [Abstract][Full Text] [Related]
18. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
Saha A; Chatterjee SK
Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]